{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-107339","form_type":"8-K","ticker":"WAT","cik":"0001000697","company_name":"WATERS CORP /DE/","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.365782+00:00","generated_at":"2026-05-15T11:18:30.886405+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M","bullets":["Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.","BDS Business Q1 FY2026 net sales $766M (down 8% YoY from $834M); net income $49M vs $78M.","Operating income fell to $35M from $94M; includes $4M integration, restructuring & transaction costs.","Pro forma condensed combined financials as of Dec 31, 2025 and for FY2025 filed as Exhibit 99.4.","MD&A for fiscal years 2023-2025 and Q1 FY2026 provided; historical allocations may not reflect stand-alone costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-107339","json":"https://secwatch.observer/filing/0001193125-26-107339.json","markdown":"https://secwatch.observer/filing/0001193125-26-107339.md","text":"https://secwatch.observer/filing/0001193125-26-107339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000697/000119312526107339/0001193125-26-107339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000697/000119312526107339/d122710d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:18:30.886405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}